Overview

First Line Ovarian Cancer Treatment - Cohort Study

Status:
Completed
Trial end date:
2016-03-01
Target enrollment:
Participant gender:
Summary
The French cooperative group GINECO proposes to implement an observational study to describe a real situation, in daily practice tolerance and methods of administration of bevacizumab (Avastin ®)
Details
Lead Sponsor:
ARCAGY/ GINECO GROUP
Collaborator:
Roche Pharma AG
Treatments:
Bevacizumab